Skip to Main Content


Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States and a significant public health problem in most industrialized nations. Since 1900, it has been the leading cause of death in the United States every year except 1918.1 In 2005, CVD afflicted 80 million Americans and caused 864,500 deaths. Meanwhile, the number of people with CVD, and especially its advanced forms, has been increasing. There are two main reasons for this. First, although there is still no cure for CVD, palliative therapy has improved to the point that more people are surviving past their initial episodes of CVD to live on with some form of the disease. Second, the average age of the US population is rising as the “baby boom” generation ages.


An increasingly prevalent form of advanced CVD is heart failure (HF). Almost 5.7 million Americans (approximately 3.2 million men and 2.5 million women) are living with HF.1 Its etiology can be ischemic, idiopathic, or viral. More than $37.2 billion is spent each year on the care of HF patients, and many therapeutic advances have been made. In 2005, HF directly caused 53,000 deaths and indirectly caused another 250,000. As large as the problem is now, its magnitude is expected to worsen as more cardiac patients are able to survive and live longer with their disease and thus increase their chances of developing end-stage HF.


At present, treatment of advanced HF takes three forms: medical therapy, surgical therapy, and cardiac support or replacement.2,3 Medical therapy (eg, intravenous inotropes and vasodilators) relieves symptoms by reducing cardiac work and increasing myocardial contractility. However, although advances in medical therapy have helped improve quality of life for those with heart failure, mortality remains unaffected. Surgical therapy (eg, revascularization and valve replacement or repair) relieves symptoms of ischemia and valvular dysfunction, but in most cases does not stop the underlying disease process from progressing. When conventional medical and surgical therapies for HF are exhausted, cardiac support or replacement (ie, heart transplantation or implantation of an artificial heart or ventricular assist device) may in some cases become the only therapeutic alternative.


Heart transplantation has evolved into a suitable treatment for advanced HF. However, it has severe limitations related to patient selection, organ procurement and distribution, and cost-effectiveness. Slightly more than 2000 patients with end-stage heart failure receive heart transplants each year in the United States. However, about 3000 patients are on the active heart transplant waiting list at any given time, and as many as 40,000 more are potential candidates for heart transplantation.4,5 Heart transplantation for the relatively young (<40 years old) is not very promising because the life expectancy of a donor heart recipient is about 10 years on average and 20 years at most. In 2004, 460 patients on the active waiting list died while awaiting a donor heart. Heart transplantation is also associated with continuous, lifelong, expensive medical therapy.


To help overcome these limitations, engineers and physicians have continued efforts begun over four decades ago to develop systems for providing either temporary or permanent mechanical circulatory support (MCS). Originally, such systems were intended to support patients indefinitely because other forms of heart replacement did not ...

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.


About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Subscription Options

AccessSurgery Full Site: One-Year Subscription

Connect to the full suite of AccessSurgery content and resources including more than 160 instructional videos, 16,000+ high-quality images, interactive board review, 20+ textbooks, and more.

$995 USD
Buy Now

Pay Per View: Timed Access to all of AccessSurgery

24 Hour Subscription $34.95

Buy Now

48 Hour Subscription $54.95

Buy Now

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.